Panakeia to attend and present at upcoming scientific and business conferences
- Apr 16
- 2 min read
Cambridge, UK, 16 April 2026 – Panakeia (“the Company”), the world’s first in silico multi-omics company, is pleased to confirm that it will be attending and presenting at a number of conferences in April and May 2026.
AACR Annual Meeting – April 17 – 22, San Diego, CA
Oral Presentation
Title: A translational deep learning platform predicts metabolic pathway activity from routine H&E slides to enable patient stratification
Abstract Presentation Number: 6726 Session: Machine Learning Approaches for Cancer Diagnosis and Treatment Prediction
Date/Time: April 21, 2026, 2:30 PM – 4:30 PM PST
Poster Presentation
Title: Functional pathway analysis reveals discordance between clinical HER2 status and downstream effector activation in breast cancer
Poster Number: 57 (Poster Section 3, Poster Board 19)
Session: Application of Bioinformatics to Cancer Biology 1
Date/Time: April 19, 2026, 2:00 PM – 5:00 PM PST
The NHS Strategy Summit – April 30, London, UK
Annual Transforming Digital Pathology & AI: The Path Forward – May 14, Edinburgh, UK
Company Presentation: Joint presentation delivered alongside one of Panakeia’s clinical partners.
The Times Life Sciences Summit – May 21, London, UK
Boston Tech Week – May 26 – 31, Boston, MA
ASCO Annual Meeting – May 29 – June 2, Chicago, IL
If you would like to meet with the Panakeia team at any of the above conferences, please get in touch via the contact form on our website.
About Panakeia
Panakeia is the world's first in silico multi-omics company, building AI solutions to uncover complete biology at scale and accelerate precision medicine research, drug discovery, development and clinical decision-making.
Panakeia's PANProfiler platform uses a biology-first AI approach to determine biomarker status across DNA, RNA, proteins, and metabolites directly from routinely used brightfield images of cells and tissues. The PANProfiler platform has been independently validated in peer-reviewed publications, including Nature Communications Medicine, where it was recognised as one of the journal's top 25 papers of 2024. Two UKCA-marked clinical products derived from the platform are deployed in hospitals, enabling faster and more accessible precision diagnostics.
To learn more about Panakeia's platform visit: https://www.panakeia.ai/
For more information please contact:
Stella Lempidaki, PhD
Head of Communications